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Abstract
Background: The Paracetamol (Acetaminophen) In Stroke (PAIS) study is a phase III multicenter,
double blind, randomized, placebo-controlled clinical trial of high-dose acetaminophen in patients
with acute stroke. The trial compares treatment with a daily dose of 6 g acetaminophen, started
within 12 hours after the onset of symptoms, with matched placebo. The purpose of this study is
to assess whether treatment with acetaminophen for 3 days will result in improved functional
outcome through a modest reduction in body temperature and prevention of fever.
The previously planned statistical analysis based on a dichotomization of the scores on the modified
Rankin Scale (mRS) may not make the most efficient use of the available baseline information.
Therefore, the planned primary analysis of the PAIS study has been changed from fixed
dichotomization of the mRS to a sliding dichotomy analysis.
Methods: Instead of taking a single definition of good outcome for all patients, the definition is
tailored to each individual patient's baseline prognosis on entry into the trial.
Conclusion: The protocol change was initiated because of both advances in statistical approaches
and to increase the efficiency of the trial by improving statistical power.
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Background
The Paracetamol (Acetaminophen) In Stroke (PAIS) Study
is a phase III multicenter, double blind, randomized, pla-
cebo-controlled clinical trial of high-dose acetaminophen
in patients with acute stroke. The trial compares treatment
with a daily dose of 6 g acetaminophen, started within 12
hours after the onset of symptoms, with matched placebo.
The purpose of this study is to assess whether treatment
with acetaminophen for 3 days will result in improved
long-term functional outcome through a modest reduc-
tion in body temperature and prevention of fever [1].
In the original protocol, the primary outcome measure is
a dichotomized score on the modified Rankin Scale
(mRS) [2] assessed at 3 months from onset of symptoms,
with good functional outcome defined as a score of 0–2
and poor functional outcome as a score of 3-death.
The common approach of dichotomizing the mRS, an
ordinal outcome scale, has several disadvantages. First, it
may not correspond with everyday clinical practice.
Dichotomized outcome analyses convert ordinal scales
into binary outcome measures. Most treatment strategies
tested in acute stroke trials are not expected to be com-
pletely curative, but to lead to improvement. Therefore, it
is also informative to show that treatment moves patients
from severe to moderate disability or from moderate dis-
ability to recovery, and not only to demonstrate differ-
ences in the numbers of patients with a good or poor
functional outcome. Secondly, dichotomization may
limit statistical power. The sample size calculation used
for the PAIS study assumes that each patient in the pla-
cebo group has a 50% probability of poor outcome at 3
months [1]. In practice, there will be substantial prognos-
tic heterogeneity because of differences in baseline varia-
bles between patients. If this is not taken into account, the
chance of finding a true treatment effect may be reduced.
Thirdly, by assessing only a single health state transition,
investigators may be forced to discard a substantial
amount of outcome information. This may lead to under-
estimation of treatment benefit or harm.
Because of these disadvantages of dichotomization, new
approaches to outcome analysis have been proposed and
tested in acute stroke trials [3-7]. These novel outcome
analyses consider the full range of the ordinal outcome
scale and lead to a single and meaningful estimate of the
treatment effect. One of these new approaches is the so-
called "sliding dichotomy" [5]. Other approaches are shift
analysis and analyses that make use of ordinal logistic
regression [3,4,7].
For the PAIS study, we decided to change the planned
analysis for the primary outcome measure from a fixed
dichotomy to a sliding dichotomy analysis. This protocol
change was initiated because of both advances in statisti-
cal approaches and to increase the efficiency of the trial by
improving statistical power.
Methods
Instead of taking a single definition of good outcome for
all patients, the definition is tailored to each individual
patient's baseline prognosis on entry into the trial. The
outcome of an individual patient is thus regarded as good
or poor depending on what would have been expected
based on the severity of stroke and other prognostic fac-
tors.
Blinded data from the PAIS study [1] were used to illus-
trate this procedure of the sliding dichotomy analysis (Fig-
ure 1). With logistic regression, a prognostic index to
estimate the probability of good outcome (defined as
mRS < 3) was generated on basis of blinded observations
in the PAIS study. The prognostic index included age, sex,
stroke severity (according to the NIHSS), previous stroke,
stroke type (hemorrhagic or ischemic), and diabetes mel-
litus.
The study population was then divided into 20 quantiles
(vingtiles) of the baseline prognostic index. The distribu-
tion of the mRS scores at three months was estimated for
each vingtile of the prognostic index. For each vingtile the
distribution of outcome mRS is given in Figure 1. Thereaf-
ter, 6 bands (clusters of vingtiles) were defined in such a
way that the median of the mRS in that band would be
equal to the next score on the mRS (1–6). Cut points
would thus be taken at vingtiles 7/8, 11/12, 14/15, 17/18,
and 19/20. The primary effect estimate will be the odds
ratio of improvement, i.e. a lower score than the median,
for patients in a particular band. For example, for a patient
of whom the prognostic risk is in the 12th vingtile, the
median predicted outcome mRS is 3 and an outcome mRS
< 3 would be taken as good outcome (Figure 1). This var-
ying bandwidth makes more efficient use of the data than
an approach based on tertiles or quartiles, as originally
proposed [5]. Note that the choice of cut point is com-
pletely independent of the treatment effect, as the data are
blinded.
Although the definition of the new primary outcome is
based on prognostic indicators at baseline, imbalances in
these and other prognostic factors between the treatment
groups may still confound the assessment of treatment
effect. Adjustments will therefore be made with a multiple
logistic regression model that includes time since stroke
onset, baseline temperature, stroke severity (as assessed
with the NIHSS), stroke type (hemorrhagic versus
ischemic), ischemic stroke subtype (lacunar versus non-
lacunar) and thrombolytic therapy, as proposed previ-BMC Cardiovascular Disorders 2008, 8:29 http://www.biomedcentral.com/1471-2261/8/29
Page 3 of 5
(page number not for citation purposes)
ously, [1] as well as for age, sex, previous stroke, atrial
fibrillation and diabetes mellitus.
Secondary effect measures will include an estimate of the
odds ratio for improvement, estimated by means of ordi-
nal logistic regression analysis.
We will also estimate the adjusted odds ratio for the
former primary outcome, i.e. good functional outcome, as
defined as a score ≤ 2, and alternative dichotomizations of
the mRS (0 to 3 versus 4 to 6). As reported before [1], the
score on the Barthel index at 3 months, body temperature
at 24 hours from start of treatment, and quality of life at
three months as assessed with the EuroQol-5D will also
be assessed.
Discussion
Several approaches to outcome analysis have recently
been applied in acute stroke trials, including shift analysis
[6], a rank test of original ordinal data, ordinal logistic
regression [3], and the concept of a sliding dichotomy [5].
Analyzing the full range of ordinal data for functional out-
come has been shown to be more statistically efficient
than collapsing data [3]. A recent study compared statisti-
cal approaches to the analysis of differences in functional
outcome as measured on ordinal scales. The authors con-
cluded that methods that made use of the full range of
ordinal outcomes were more sensitive to treatment effects.
However, in this study methods that incorporate baseline
prognostic information, such as the sliding dichotomy,
could not be evaluated [3].
Shift analysis [6] is not a formal test, but a calculus to esti-
mate the proportion of patients moving from one cate-
gory on the ordinal scale to the next. This can be a useful
measure to gain insight in the size of a treatment effect. A
disadvantage of shift analysis is that the uncertainty con-
Distribution of predicted outcome scores on the modified Rankin Scale [2] at three months over ordered vingtiles of a prog- nostic index for good outcome in the PAIS trial [1] Figure 1
Distribution of predicted outcome scores on the modified Rankin Scale[2]at three months over ordered 
vingtiles of a prognostic index for good outcome in the PAIS trial[1]. Six bands were defined in such a way that the 
median of the mRS in that band was equal to the next score on the mRS (1–6). Cut points were taken at quantile 7/8, 11/12, 
14/15, 17/18, and 19/20.BMC Cardiovascular Disorders 2008, 8:29 http://www.biomedcentral.com/1471-2261/8/29
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cerning the effect estimate cannot be quantified, as in sta-
tistical effect estimation.
The term 'shift test' is used to designate the Mantel-Haen-
szel (CMH) test that compares two ordered outcome dis-
tributions after adjusting for one or more baseline
variables. The test provides a p-value, but not an effect
estimate. The Van Elteren variant of the test was employed
in the analysis of the results of the GAIN trial [8] and in a
post-hoc analysis of NINDS and ECASS-2 trials [9] Ordi-
nal logistic regression was used to estimate an effect size
with its corresponding 95% confidence interval.
Classic statistical methods to compare distributions on an
ordinal scale require rank tests. Translation of the results
of a rank test (a p-value) to an estimate of the treatment
effect is not straightforward; this may be done either by
shift analysis (with the aforementioned drawbacks) or by
ordinal logistic regression. This analysis does not make
use of the available baseline information. Ordinal logistic
regression may be used to estimate treatment effects in
studies with ordered outcomes. The relative risk of a tran-
sition is estimated as an odds ratio. An assumption is that
any treatment effect is similar across outcome levels, i.e.
the odds of moving from mRS level 3 to 2 are similar to
the odds of moving from level 5 to 4. In the Optimizing
Analysis of Stroke Trials (OAST) study, a study to assess
which statistical approaches are most efficient in analyz-
ing outcomes from stroke trials, the assumption of pro-
portional odds was not met in 8 of the 55 datasets
according to the authors, but they did not specify how
they tested for this assumption [3]. Furthermore, this
method might be inefficient when treatment effects clus-
ter at one transition. When this approach was tested in a
large dataset of patients with severe head injury, it did not
perform better than the sliding dichotomy [5]. Effect esti-
mates should be meaningful from a clinical point of view.
In ordinal logistic regression, meaningful interpretation is
hampered by the point that moving 1 category up on the
mRS may have a different clinical interpretation when it
concerns low mRS scores, compared to high mRS scores.
In our view, these are important arguments for not using
ordinal regression in the primary outcome analysis.
An advantage of the sliding dichotomy approach is that it
makes the least assumptions about the type of patients
who will be included in the study, the type of outcome
they will experience, and the treatment effect pattern the
treatment strategy under study will exert. It provides a
simple outcome measure that is relatively easy to inter-
pret, i.e. the relative risk of improvement beyond the level
that could be expected from baseline prognostic informa-
tion [5]. To our opinion, this approach is to be preferred
in the analysis of treatment effects employing the full
range of outcomes on the mRS. With the concept of slid-
ing dichotomy, each individual patient's baseline progno-
sis is taken into account. This approach may be more
relevant for clinical practice and may improve statistical
power, as patients at the prognostic extremes have the
potential to contribute to the estimation of the treatment
effect.
An exact, parametric approach to sample size estimation
for studies that make use of the sliding dichotomy
approach for ordered categorical outcome variables is not
available. Simulation studies of randomized clinical trials
in traumatic brain injury that made use of the Glasgow
Outcome Scale, [10] suggest that " substantial gains in sta-
tistical efficiency can be made". Either of these approaches
along with adjustment for baseline covariates gave effi-
ciency gains equivalent to reducing the required sample
size by up to 50% [5,11].
We realize that this approach may also have disadvan-
tages. Patients, care givers, and clinicians may consider the
results of this way of analysis more difficult to interpret
than collapsing data into a binary outcome. We wonder
whether this is really the case. Taken at face value, a tran-
sition across the boundary between mRS 2 and mRS 3
does not tell us much at all about the real health benefit
of a treatment, and a common odds ratio based on sliding
dichotomy, may be in fact more informative for those
who have grown accustomed to it.
Conclusion
In summary, because of the drawbacks of dichotomiza-
tion, the primary outcome analysis of the multicenter
acute stroke trial PAIS has been changed from fixed
dichotomy of the mRS to the sliding dichotomy analysis.
It has been approved by the PAIS steering committee on
April 1, 2008, before inclusion into the trial was com-
pleted. This approach may be more relevant for clinical
practice and is expected to increase the efficiency of the
trial by improving statistical power
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